Liquid chromatography-tandem mass spectrometry - Application in the clinical laboratory by Vogeser, Michael
Clin Chem Lab Med 2003; 41(2):117–126 © 2003 by Walter de Gruyter · Berlin · New York
Michael Vogeser*
Institute of Clinical Chemistry, Ludwig-Maximilians
Universität München, Munich, Germany
This review provides a concise survey of liquid chro-
matography-tandem mass spectrometry (LC-TMS) as
an emerging technology in clinical chemistry. The com-
bination of two mass spectrometers with an interposed
collision cell characterizes LC-TMS as an analytical
technology on its own and not just as a more specific
detector for HPLC compared with conventional tech-
niques. In LC-TMS, liquid chromatography is rather
used for sample preparation but not for complete reso-
lution of compounds of interest. The instrument tech-
nology of LC-TMS is complex and comparatively expen-
sive; however, in routine use, methods are far more
rugged compared to conventional chromatographic
techniques and enable high-throughput analyses with
very limited manual handling steps. Moreover, com-
pared to both gas chromatography-mass spectrometry
(GC-MS) and conventional HPLC techniques, LC-TMS is
substantially more versatile with respect to the spec-
trum of analyzable compounds. For these reasons it is
likely that LC-TMS will gain far more widespread use in
the clinical laboratory than HPLC and GC-MS ever did. In
this article, the key features of LC-TMS are described,
method development is explained, typical fields of ap-
plication are discussed, and personal experiences are
related. Clin Chem Lab Med 2003; 41(2):117–126
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Introduction
While chromatography and mass spectrometry repre-
sent key technologies in biomedical research, their ap-
plication in the setting of the clinical laboratory has re-
mained limited and restricted to rather few specialized
laboratories. This is explained by the fact that these
methods require – in contrast to contemporary clincical
chemistry and immunoassay analyzers – very skillful
handling and often cumbersome troubleshooting. 
Typical applications of high-performance liquid
chromatography (HPLC) in clinical chemistry are, for
example, the quantification of urinary catecholamines
and metabolites (metanephrines, vanillin mandelic
acid, homovanillinic acid), of urinary 5-hydroxyindole
acetic acid and serotonin, porphyrins, the measure-
ment of serum vitamin A, E, B1, B6 concentrations, and
the monitoring of some drugs (e.g., amiodarone and
itraconazole). Other HPLC methods compete with com-
mercially available automated immunoassays (e.g., 25-
OH-vitamin D; homocysteine, desoxypyridinolin). Typ-
ical clinical applications of gas chromatography-mass
spectrometry (GC-MS) are the quantification of organic
acids and amino acids, profiling of fatty acids, and the
detection of drugs of abuse and toxic compounds in
forensic and environmental medicine, in addition to
the search for inborn errors of metabolism.
Methodology of GC-MS
In GC-MS, the volatile eluent from the several meters
long GC-capillary column is introduced directly into a
high-vacuum area; here the compounds are ionized
and disintegrated by the impact of accelerated elec-
trons generated by a heated filament. This “electron
impact” (EI-) ionization is disintegrating; the intact mol-
ecular ion is usually not generated. The fragments are
then “filtered” according to their specific mass-to-
charge ratio (m/z), as most widely used by a system of
four parallel metal bars under a radiofrequency elec-
tromagnetic field (quadrupole) or a strong magnetic
field. At a specific pattern of the radiofrequency field
only molecules of one defined m/z ratio can pass the
quadrupole and reach the detector, where electrons are
liberated from an aluminum block. These secondary
electrons generate a light signal on a membrane of
phosphorus that is multiplied and quantified. Within a
second or less the passing m/z ratios can be scanned
over a range of 0 to about 800. Using this scan mode a
disintegration spectrum of a compound eluted at a cer-
tain time point from the GC can be acquired; usually
several typical fragment ions of an individual com-
pound can be found reproducibly in the manner of a
“fingerprint”. This scan mode enables the identifica-
tion of unknown compounds in biological materials by
comparison with libraries of disintegration spectra. For
*E-mail of the corresponding author:
mvogeser@klch.med.uni-muenchen.de
Review
Liquid Chromatography-Tandem Mass Spectrometry – Application in
the Clinical Laboratory
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 12:25
118 Vogeser: Liquid chromatography-tandem mass spectrometry
quantification applications, however, usually the
quadrupole alternates just between one typical frag-
ment ion of the analyte and one fragment ion of an
added internal standard compound to pass (selected
ion recording, SIR). GC-MS has been in use in special-
ized clinical laboratories since the early ‘70s and en-
ables highly specific and sensitive quantification of a
limited number of certain medically important volatile
compounds; polar compounds have to be derivatized
prior to GC to offer appropriate volatility.
Methodology of Liquid Chromatography Mass
Spectrometry (LC-MS)
With the development of HPLC technologies in the late
‘70s and early ‘80s the application of mass spectrometry
as a detection principle for this more versatile chromato-
graphic technique became tempting. However, the tech-
nical problems of LC-MS coupling are enormous. In GC-
MS, the ionization of the volatile chromatographic eluent
is performed within the high-vacuum region of the in-
strument; given typical GC-flow rates of 1 ml of helium
per minute, turbomolecular vacuum pumps are capable
of maintaining adequate vacuum within the instrument
to allow ions to pass relevant distances without collision
with air constituents. A direct flow of the liquid eluent of
HPLC into, and evaporation of, the solvent within a mass
spectrometer would produce enormous volumes of gas
and a vacuum could never be maintained. Therefore, it
was necessary to achieve evaporation of the solvents
and ionization of the analytes outside the high-vacuum
region at atmospheric pressure to make mass spectrom-
etry applicable to HPLC.
Atmospheric pressure ionization
In this key feature of LC-MS technology, most com-
monly a 10%-split fraction of the HPLC eluent flow is
sprayed through a capillary assisted by a flow of pres-
surized nitrogen to form an aerosol. The capillary bears
a charge of 2.0–3.5 kV and consequently strong electri-
cal charge is transferred to the droplets of this spray
(“electrospray”). The aerosol is dried by a high flow of
nitrogen (about 70 l/min) at a temperature of
200–300 °C; thus the HPLC solvent is evaporated from
the droplets, they undergo a reduction in size, and the
surface charge increases rapidly leading to the so-
called Coulomb reaction. This produces new genera-
tions of smaller droplets until they have attained a suf-
ficient charge density to allow sample ions to be
ejected from the surface of the droplets (“ion evapora-
tion”; Figure 1). In this way ionization is achieved
within a distance of few millimeters from the tip of the
capillary. The principle of electrospray ionization has
been honored by the Nobel Prize in Chemistry 2002.
Despite the high temperatures of nitrogen involved in
this process, molecules do not experience thermal
damage since the evaporation of large volumes of sol-
vents is “chilling” the analytes. The entrance cone to
the vacuum region of the instrument, with a diameter
of less than 1 mm, is situated in an orthogonal position
to the direction of the electrospray and bears a counter-
charge with respect to the charge of the capillary.
Based on this principle, only ionized molecules enter
the vacuum, whereas un-ionized and non-volatile mol-
ecules of the matrix remain outside. The high vacuum
inside an LC-MS system is maintained by turbomolec-
ular pumps (running with about 100000 revolutions per
minute), which are substantially more powerful com-
pared to pumps used in GC-MS. From the entrance
cone, ions are directed into a quadrupole by “ion-op-
tics”, where a specific radiofrequency pattern allows
just one single defined mass-to-charge ratio of ions to
pass to the detector, as in GC-MS. Commonly, analyte
molecules acquire one proton during atmospheric
pressure ionization forming a “quasi-molecular” ion
([M+H+]) but also cluster formation with sodium, potas-
Figure 1 Scheme of the principle of electrospray atmospheric pressure ionization.
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sium, or constituents of the mobile phase as ammo-
nium or formiate ions can occur. Electrospray ioniza-
tion represents a technique of “soft” ionization since
usually the intact analyte molecule is generated in con-
trast to the disintegrating ionization in GC-MS.
An alternative technique to electrospray ionization is
atmospheric pressure chemical ionization (APCI),
where a corona discharge near the eluent spray trans-
fers a charge to the droplets. APCI is in general better
suited for the ionization of less polar compounds.
Single-stage MS
The first systems that combined HPLC with mass spec-
trometric detection involved one single quadrupole an-
alyzer as described above (“single-stage MS”). These
instruments offer the possibility to detect compounds
lacking molecular properties that are the prerequisite
for conventional HPLC detection techniques, such as
UV absorption (e.g., by an aromatic structure), fluores-
cence (as potentially found with conjugated double
bonds), or characteristic electrochemical behavior. Fur-
thermore, due to the detection according to mass-to-
charge ratios, the specificity of these single-stage sys-
tems is superior to conventional techniques of HPLC
detection. However, given the extreme complexity of
biological samples with many completely different
compounds of identical molecular mass and the gen-
eral possibility of multiple charging of analytes in elec-
trospray ionization (e.g., a molecule with a molecular
mass of 20000 that has accepted 10 protons has an m/z
of 200 just like a singly-charged molecule of a molecu-
lar mass of 200), single-stage LC-MS still requires base-
line chromatographic separation of relevant com-
pounds if applied to samples of biological origin. For
application in the clinical laboratory, therefore, the
same practical problems in handling apply to single-
stage LC-MS as is the case for conventional HPLC tech-
niques. For application with GC the principle of the sin-
gle-stage quadrupole technique is sufficiently specific
for biomedical analyses due to the enormous separa-
tion capacity of capillary gas chromatography, which
HPLC lacks.
Tandem mass spectrometry (TMS)
The essential step in the development of LC-MS as a
routine technique for the clinical laboratory was the in-
troduction of collision-induced dissociation (CID) with
a second quadrupole for analysis of the fragments gen-
erated in this way (“tandem”-MS): In these instru-
ments, a first quadrupole selects the molecular (“par-
ent”) ion of the respective analyte, which is then
directed into a collision cell; here a very low flow of ar-
gon enters as the collision gas. By collision with these
argon molecules the parent ions are disintegrated into
several typical so-called “daughter” or “product ions”.
These daughter ions can then be scanned according to
their respective m/z ratio by a second quadrupole posi-
tioned behind the collision cell within 1 second or less
(Figure 2). Whereas in GC-MS a fragmentation “finger-
print” is generated on ionization by electron impact it-
self, in LC-TMS a “fingerprint” spectrum arises from
controlled disintegration of selected intact parent ions
within the collision cell. 
By analogy to the selected ion recording mode of
GC-MS for quantification with LC-TMS, usually the sec-
ond mass spectrometer is set to the m/z ratio of one
characteristic daughter ion of a respective parent ion
(multiple reaction monitoring, MRM). Such “transi-
tions” are usually given as, for example, “931>864”,
with 931 the mass-to-charge ratio of the parent ion, and
864 the mass-to-charge ratio of the production ion
(mass-to-charge ratios are given for the compound
sirolimus as an example). 
Since the collision cell in principle represents a small
quadrupole on its own instead of the term “tandem
mass spectrometer”, the term “triple stage mass spec-
trometer” can be used synonymously.
Using the principle of tandem configuration of two
quadrupoles the specificity of LC-MS was increased
substantially compared to single-stage systems, fully
compensating for the limited separation capacity of
HPLC compared to GC. Once these LC-TMS systems be-
came available, a widespread use in the field of pharma-
cokinetic research studies by commercial laboratories
began (1); within a few years LC-TMS replaced conven-
Figure 2 Scheme of the main elements of a tandem mass
spectrometry system. In quadropol 1 (Q1) ions are filtered ac-
cording to their mass-to-charge ratio (m/z) and a respective
parent ion is selected; the selected ions undergo collision-in-
duced decomposition in the collision cell (CC); in quadrupole
2 (Q2) the fragment ions are filtered according to their mass-
to-charge ratio and a specific ion is selected, which is finally
detected by the photomultiplier detection system.
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tional HPLC and GC-MS techniques almost completely
for these purposes by the end of the ‘90s, especially
since the highest attainable analytical standard is gener-
ally required in studies addressing drug licensing.
Contemporary LC-TMS systems are bench top instru-
ments with a footprint of approximately 1 × 1.5 meters.
At present three manufacturers offer LC-TMS systems
that are applicable in the clinical laboratory (Applied
Biosystems, Foster City, CA, USA; Micromass, Man-
chester, UK; ThermoFinnigan, San Jose, CA, USA) with
list prices ranging from about 200000 to 500000 Euro.
The systems are comprised of user-friendly software
packages that control the mass spectrometers, as well
as the HPLC module and the autosampler and integrate
all functions of data acquisition and quantification.
LC-TMS offers the possibility to skip between multi-
ple MRM traces in time steps of fractions of seconds;
up to eight parallel MRM traces can usually be analyzed
without loss of sensitivity but potentially up to 20
traces can be acquired simultaneously. A typical LC-
TMS chromatogram is given in Figure 3. 
As shown in Table 1, LC-TMS offers essential advan-
tages compared to both GC-MS and HPLC with con-
ventional techniques of detection despite some spe-
cific limitations that are discussed below.
Method Development with LC-TMS
Mass spectrometric conditions
The development of an LC-TMS method is usually very
straightforward compared to the development of con-
ventional HPLC methods or even of immunoassays.
The first step is the continuous infusion of a solution of
the pure analyte substance into the mass spectrometer
to optimize the conditions of ionization, which usually
takes a few minutes. When the parent ion of the re-
Figure 3 Typical chromatogram of a liquid chromatography
tandem mass spectrometry method: determination of cortisol
and cortisone with tri-deuterated cortisol as the internal stan-
dard (16). The respective parent and product ions are 366.1>312
for tri-deuterated cortisol, 361.1>163 for cortisone, and
363.1>309 for cortisol. Note the co-elution of cortisol and tri-
deuterated cortisol.
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spective analyte is generated at optimum intensity a
disintegration spectrum of that parent ion is recorded
applying the collision gas. From this disintegration
spectrum an intensive product ion is selected for multi-
ple reaction monitoring; accordingly the collision
energy and few parameters of the ion optics and
quadrupoles are tuned to obtain maximum product ion
intensity. Usually a standard mobile phase can be used
for the mass spectrometric optimization of most ana-
lytes (for example a mixture of acetonitrile and water-
containing ammonium acetate or formic acid as a pro-
ton donor). However, in some cases ion yield can be
improved by modification in the composition of the
mobile phase. After defining the analyte-specific pair of
parent ion and product ion (“transition”), the sensitiv-
ity is tested by injection of the pure compound solution
from a sample loop at decreasing concentrations into
the instrument. With these few steps the mass spectro-
metric method set-up for a single compound is finished
and is then performed in the same manner for all com-
pounds that are intended to be quantified with one
method. As the next step sample preparation and chro-
matographic conditions are elaborated.
Sample preparation
Sample preparation is necessary for LC-TMS analyses
of biological samples since introduction of crude
plasma or urine into the atmospheric pressure ioniza-
tion source could inhibit the ionization of analytes of in-
terest (“ion suppression”) and would cause rapid spoil-
ing of the ion source. 
Depending on the concentration range of target ana-
lytes simple protein precipitation (for example with
acetonitrile) may be sufficient to obtain acceptable re-
sults for many analytes. Lower target concentrations
require larger sample volumes to be injected. However,
residual matrix compounds present after mere protein
precipitation will limit the lifetime of the analytical
columns. Furthermore, co-elution of residual matrix
compounds together with the analytes of interest may
limit the sensitivity of detection by ion suppression
LC-TMS GC-MS Conventional HPLC
Prerequisite for detection of
specific analytes
Efficient ionization of most an-
alytes is possible irrespective
of their molecular structure;
no limitation by molecular
mass.
Limited molecular mass
(< 800); analytes have to be
thermically stable and volatile
per se or by derivatization.
For detection chromophores
(e.g., aromatic structures) are
necessary for UV-detection,
conjugated double bonds for
fluorescence detection or cha-
racteristic redox properties
for electrochemical detection.
Sample preparation Mostly limited to rough
removal of matrix proteins.
No need for derivatization
(most assays).
Complex and laborious; since
the entire GC-eluent enters
the high-vacuum region
residual matrix compounds
cause spoiling of these parts;
cleaning requires venting of
the system and is very
laborious.
Need for derivatization of the
analytes, therefore typically
sample preparation in several
steps. Moreover, the
completeness of
derivatization in individual
samples is always
speculative.
Mostly complex and
laborious; due to the limited
resolution capacity of HPLC,
analytes of interest have to be
concentrated and separated
specifically by sample
preparation for example
using solid-phase extraction
cartridges.
Chromatographic separation Very limited chromatographic
separation needed since
several multiple reaction
monitoring traces can be
detected in parallel by
alternating MS-acquisition.
Co-elution of several
compounds does not hinder
quantitative analysis.
High intrinsic resolution
capacity of GC is necessary
since usually the quantified
fragments are merely
characterized by one mass-to-
charge ratio. In biological
samples, however, this offers
very limited specificity. GC-
tandem MS systems exist but
are not widely used.
Due to the poor specificity of
all detection principles used
for conventional HPLC (UV-
VIS, electrochemical, and
fluorescence detection),
minute base-line separation
of analytes is necessary; since
the resolution capacity of LC
is very much limited
compared to GC; often
complex mobile phase
mixtures with specific
gradient programs are
necessary.
Table 1 Characteristic features of liquid chromatography-
tandem mass spectrometry, gas chromatography-mass spec-
trometry and conventional high-performance liquid chro-
matographic techniques.
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when mere protein precipitation and limited chro-
matography is applied. Ion suppression may be mini-
mized by extended analytical run times that – on the
other hand – limit the throughput of the expensive in-
strument (2). For these reasons in many applications
liquid-liquid or solid-phase extraction is favorable. The
latter approach can be automatized easily either by off-
line sample handling systems with disposable car-
tridges or by on-line solid phase extraction with
permanently used extraction columns and column-
switching technique for on-line transfer to analytical
chromatography (3–5). Both liquid-liquid and solid-
phase extraction may include a concentration step and
can thus increase the sensitivity of a method.
Chromatography 
Despite the high (seemingly inherent) specificity of
TMS, some degree of further chromatographic clean-
up of the analyte after sample preparation is reason-
able in order to separate the analyte of interest, espe-
cially from more hydrophilic conjugate metabolites.
Such conjugates can potentially disintegrate during at-
mospheric pressure ionization (“in-source transforma-
tion”) and can cause falsely high signal of the actually
unconjugated compound if chromatography does not
resolve between conjugated and unconjugated com-
pounds (6, 7). Chromatography also can improve the
ionization yield of the compounds of interest since
“ion-suppression” may occur if the analytes co-elute
with residual compounds of the sample matrix. Chro-
matographic run times of about 3–5 minutes are ap-
propriate. Due to the high specificity of TMS and the
possibility to acquire several MRM traces simultane-
ously, however, time-consuming and cumbersome op-
timization of the HPLC conditions (eluents, gradient
programs, column materials, temperature, flow rates)
with the goal of baseline resolution of all relevant com-
pounds is not necessary as is the case with conven-
tional nonspecific techniques of HPLC detection. Co-
elution of relevant analytes is useful rather than being
a problem. For some applications – depending on tar-
get analyte concentration – chromatography can in-
deed be omitted completely as for neonatal screening
for inherited errors of metabolism (8).
Internal standards
LC-TMS principally requires the use of internal stan-
dards; solutions of these compounds are added to
samples and calibrators of a series strictly in the same
quantity, and quantification is based on the ratio of the
peak area of the target compound to that of the internal
standard trace (= response) in samples and calibrators.
Ionization conditions and ion yield often vary within
seconds with atmospheric pressure ionization; it is the
essential requirement for an internal standard com-
pound that this “undulation” of ionization efficiency
has equal impact on the target analyte and the internal
standard molecule, respectively; therefore, both com-
pounds should be as similar as possible with regard to
their molecular structure. This is given best in stable
isotope-labeled internal standard compounds where
three or more hydrogen atoms of the target analyte are
replaced by deuterium or carbon-12 atoms are re-
placed by carbon-13 atoms. Corresponding to the num-
ber of stable isotope atoms introduced into an internal
standard molecule, the molecular weight is higher by
one atomic mass unit compared to the naturally occur-
ring compound. However, the chemical behavior dur-
ing extraction, as well as the properties of ionization,
are almost identical to that of the unlabeled analyte.
Consequently, methods employing stable isotope-la-
beled internal standards offer highest precision and ac-
curacy. Alternatively to stable isotope-labeled internal
standards, molecular homologues of the target ana-
lytes may be used (such as desmethyl homologues),
but the applicability has to be validated thoroughly. In-
deed, the availability of suitable internal standards is
crucial for the development of an individual LC-TMS
method.
Applications of LC-TMS
Neonatal screening
The first important step of LC-TMS technology into
clinical medicine was the application to newborn
screening of inherited metabolic disorders. In 1997,
Rashed et al. (8) described a multi-method for the
quantification of amino acids and acylcarnitines in
dried blood spot samples of newborns. The method
employs simple loop injection without chromatogra-
phy and allows the analysis of up to 1000 samples with
a single instrument per day (9). Using this approach the
early diagnosis of a large number of inborn metabolic
diseases has become possible that are missed by the
current conventional screening merely for phenylke-
tonuria. Namely, rare errors of amino acid metabolism
(such as maple syrup disease), defects of fatty acid ox-
idation (such as carnitine deficiency), and errors in the
metabolism of organic acids (as methylmalonaciduria)
(10, 11) are missed. The results of LC-TMS screening
offer the possibility to initiate specific diets and to pre-
vent severe disease manifestation with mental retarda-
tion or sudden death in identified children. This ex-
tended screening panel based on LC-TMS is currently
being applied in a growing number of regions world-
wide and experiences continuously widen its use at
present. Since severe lifelong disability can be avoided
by using these screening programs, they are highly
cost-effective despite the fact that thousands of analy-
ses must be performed to detect one affected child. The
diagnosis of phenylketonuria, as one of the most fre-
quent inborn metabolic errors, is improved substan-
tially by TMS compared to conventional chemical
methods since in TMS the more reliable phenylala-
nine/tyrosine ratio is determined; consequently, the re-
call rate to initiate further diagnostic work-up has been
reduced substantially by TMS. 
Usually neonatal screening investigations are per-
formed in few centers for large populations.
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Sirolimus
For applications beyond newborn screening, LC-TMS
systems were introduced into medical laboratories from
the end of the ‘90s on, mainly, however, for research pur-
poses. A further important step in the development of
LC-TMS as a routine clinical chemistry technique was
the therapeutic drug monitoring of the novel immuno-
suppressant sirolimus (syn. rapamycin). For the preven-
tion of organ rejections after transplantation this drug
offers important advantages over conventional im-
munosuppressants such as the calcineurin-inhibitors
cyclosporine or tacrolimus. Most importantly, nephro-
toxicity is absent; moreover, sirolimus exerts anti-prolif-
erative properties and may thus prevent graft-vessel
disease after heart transplantation and nephrosclerosis
after renal transplantation. During clinical studies for ap-
proval of the drug the need for dosage individualization
according to whole blood drug concentrations became
evident. This is due to poor and variable absorption and
to the inter-individually heterogeneous metabolization
of sirolimus. During these studies an automated im-
munoassay for the quantification of sirolimus was avail-
able, however, this test was withdrawn by the manufac-
turer before approval of the drug. Therefore, alternative
methods were the prerequisite for the clinical introduc-
tion of sirolimus. Since sirolimus has a very poor UV ab-
sorption conventional HPLC techniques are cumber-
some and hardly applicable for routine drug monitoring.
LC-TMS in contrast proved to be excellently suited for
the quantification of sirolimus in whole blood (5, 12).
With the availability of these analyses at the site of trans-
plantation centers the introduction of sirolimus became
possible in 2001. The very favorable clinical experiences
with sirolimus now suggest that it will become the es-
sential standard drug in transplantation medicine. In-
deed, at present the need to monitor lifelong sirolimus
treatment in transplant patients is the most important
single reason to equip laboratories of tertiary care hos-
pitals with LC-TMS systems.
General characteristics of LC-TMS applications
Once available in the setting of these respective tertiary
care clinical laboratories, the specific options of LC-TMS
for routine clinical chemistry applications now become
evident. This is documented by a continuously growing
number of published method protocols for clinically rel-
evant analytes like cyclosporine, tacrolimus (4), urinary
catecholamines (13), and metanephrines (14), busul-
fane (15), or porphobilinogen (16), which each offer sub-
stantial advantages over so far available methods. 
In general, LC-TMS is highly attractive for target an-
alytes where
i) sufficiently specific test antibodies cannot be gener-
ated for use in immunoassays (e.g., biogenous
amines such as catecholamines; vitamins (17); por-
phyrins and precursors; endogenous metabolites
such as asymmetric dimethyl arginine (ADMA) (18);
17-α-OH-progesterone (19); dihydrotestosterone;
conjugate metabolites of steroid hormones);
ii) several related compounds are to be quantified si-
multaneously in one analytical run (e.g., typically co-
administered drugs like sirolimus and tacrolimus (4)
or an active drug compound together with an active
metabolite such as itraconazole and hydroxy-itra-
conazole, or a hormone together with its pro-hor-
mone such as cortisol and cortisone (20)).
Therapeutic drug monitoring
Conventional HPLC techniques are usually considered
highly specific, but even given a symmetric peak
shape, it must always be suspected that drug metabo-
lites co-elute with the target drug compound. Many
drugs undergo extensive metabolism, especially by
the hepatic cytochrome P450 system leading to a vari-
ety of often poorly characterized metabolites. Only
very rarely are these metabolites available as pure sub-
stances to allow the conclusive investigation of the an-
alytical specificity of respective HPLC or immunoassay
methods. With LC-TMS, however, the probability that a
multiple reaction monitoring signal, characterized by
the molecular mass of the parent ion and the mass of a
product ion, is generated by an inactive metabolite of a
respective drug, by a different drug, or by an endoge-
nous compound, principally exists but is very low. Due
to this specificity, LC-TMS represents to date the ideal
technology for therapeutic drug monitoring.
In general, it is probable that therapeutic individual-
ization according to drug concentrations in blood will
gain further importance in the future. In the case of the
relatively old drug ribavirin, for example, it became evi-
dent from recent research that target concentration-tai-
lored dosage regimens essentially improve the thera-
peutic outcome in hepatitis C infection (in combination
with interferon (21)). A respective LC-TMS method em-
ploying a stable isotope-labeled internal standard has
been described (22). It is very likely that in many other
drugs for which standard dosages are usually applied,
individualization will improve therapeutic outcome,
such as with antidepressants, anti-infectives in inten-
sive care patients, anti-neoplastic drugs, or retroviral
protease inhibitors.
Reference methods
In addition to the routine application in clinical labora-
tories, LC-TMS has the potential for the development
of clinical chemistry reference methods for low-molec-
ular weight analytes (3, 19). Classically, GC-MS has
been used for this purpose. These conventional meth-
ods, however, are very laborious and their use is re-
stricted to small investigational series. It is a more im-
portant limitation of GC-MS reference methods that
they involve derivatization and the completeness of de-
rivatization and the stability of derivatives in individual
samples is always speculative. Therefore, it is likely
that the LC-TMS will be preferred for the development
of reference methods in the future. 
Despite the specific limitations discussed below, a ma-
jority of clinically relevant low-molecular weight com-
pounds can be subjected to LC-TMS analyses, whereas
only a minimal proportion is analyzable with GC-MS.
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Most importantly, this technique is limited to molecules
below a mass of about 800 and to thermostable, apolar
compounds. A further substantial difference between
GC-MS and LC-TMS is the minimal extent of mainte-
nance that is required by the latter technique. Methods
are far more rugged compared to conventional chro-
matographic techniques and the practicability in a rou-
tine setting is substantially improved. For these reasons
it is most likely that in the coming years LC-TMS will gain
wider use in clinical laboratories than GC-MS ever did. 
The technique of LC-TMS is highly versatile, and
used complementary to immunoassays it will extend
the analytical spectrum of the clinical laboratory for im-
portant analytes. LC-TMS will enable a higher degree
of independence from commercial assay manufactur-
ers for the clinical laboratory with respect to the selec-
tion of assays offered to clinicians and with respect to
the quality and cost of the products. In Table 2, typical
features of LC-TMS technology are compared with im-
munoassay applications.
The costs for the implementation of LC-TMS tech-
nology are indeed high but roughly in the same range
as the costs of contemporary immunoanalyzers; a cer-
tain decline in the price of LC-TMS instruments – as
seen with GC-MS systems – can be expected in the
coming years but the systems will remain substantially
more expensive than conventional HPLC systems.
Personal Experiences
In our laboratory, an LC-TMS system has been in use
since 2000 mainly for therapeutic drug monitoring of
sirolimus and other immunosuppressants. At a continu-
ously high workload the instrument and the method (5)
have proven to be extraordinarily rugged, with monthly
coefficients of variations below 5%. The specific require-
ments of a clinical laboratory are fully met by the sys-
tem; in particular no malfunction occurred that would
have delayed reporting of the results that are essential
for therapeutic decisions. The only regular maintenance
procedure that is necessary at an interval of several
months is cleaning of some parts of the ion source,
which requires about 1 hour without venting the system
and the exchange of HPLC columns after several thou-
sands of analyses. The system is run by ordinarily
trained medical technicians guided by a physician. Run-
ning costs per analysis are about 2.5 Euro compared to
typical costs of 15 to 30 Euro for immunoassay tests for
the quantification of immunosuppressants.
Limitations of LC-TMS
The sensitivity of LC-TMS systems still presents some
limitation. In our experience with an instrument built in
1999, for most analytes a detection limit of about 1 µg/l
can be achieved, which is sufficient for monitoring of
most drugs and the analysis of important hormones.
Sample preparation procedures that include a concen-
tration step (e.g., evaporation) may lower the limits of
detection. However, compounds like plasma meta-
nephrines are still a challenge for LC-TMS method de-
velopment but technical improvements of the instru-
ments will most probably increase the sensitivity of the
systems. 
Table 2 Characteristic differences between LC-TMS and immunoassays.
LC-TMS Immunoassays
Very straightforward and versatile assay development (if
pure substance and appropriate internal standard
compounds are available)
Assay development with production of antibodies is hardly
possible for clinical laboratories; therefore complete
dependence on assay manufacturers with respect to assay
development and analytical performance
Quantification of multiple analytes within one analytical run
is possible (e.g., main drug compound and metabolites or
typically co-administered drugs); very high specificity
Determination of merely one analyte; often limited specificity
and relevant cross-reactivity with related compounds (e.g.,
inactive cumulant drug metabolites)
Limited sample throughput. Typical run time about 5 min;
technical perspective of multiplexing with substantially
increased throughput.
At present most assays include manual steps in sample
preparation but offer the perspective of full automation
In automated assays high sample throughput (up to or even
above 100 tests per hour) without manual handling steps
High costs for instruments, very limited running costs (vials,
solvents, standards, columns)
Costs for instruments (immunoanalyzer) often lower
compared to TMS but typically very high running costs per
test for reagents and services
Sensitivity of currently used instruments for most analytes
limited to about 1 µg/l if no concentrations steps are included
in the sample preparation
Often very high sensitivity (e.g., 10 ng/l for estradiol)
Best suited for measurement of small molecules Best suited for measurement of macromolecules (e.g.,
proteohormones)
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The specificity of LC-TMS is in general very high,
however, it should principally be questioned; it can be
limited by the already mentioned effect of in-source
transformation. Nonspecificity may also arise, for ex-
ample if active and inactive metabolites of a drug have
identical molecular masses but groups of the molecule
are present at different sites and these isomers also
share common fragments in collision-induced disinte-
gration. Multiple-charged macromolecules from the
sample matrix may generate a variety of multiply-
charged product ions and thus potentially the MRM
transition of an analyte of interest may be matched.
However, in these cases – if applying appropriate chro-
matography – atypical and distinguishable peaks are
generated from multiply charged macromolecules. 
It is not the case that virtually all low-molecular com-
pounds are ionizable by atmospheric pressure ioniza-
tion. Rather apolar compounds may be ionized more
efficiently by use of APCI instead of the more widely
used electrospray ionization (ESI). In all available sys-
tems, it is possible to switch between APCI and ESI
within minutes. However, at present, with chemical
ionization as well for analytes like cholesterol epox-
ides, no sufficient ionization is achievable to allow
quantification at naturally occurring concentration lev-
els. A further example for low ionization yield is
methylmalonic acid, where a simple derivatization is
necessary to achieve sufficient ionization (23). In some
compounds, ionization is efficient but collision-in-
duced disintegration fails to generate characteristic
product ions for MRM, especially if sodium adducts of
the respective analyte are dominating. 
One potentially important advantage of GC-MS over
LC-TMS is the fact that ionization and disintegration
are achieved in GC-MS following worldwide standard-
ized conditions, namely, electrons that are accelerated
with 70 eV and helium as the carrier gas. Therefore, it
was possible to generate GC-MS spectra libraries that
can be searched electronically for unknown com-
pounds in clinical samples (like unexpected poisons)
and may thus allow their identification. This is of es-
sential importance in legal medicine and toxicology. In
LC-TMS, in contrast, the specific architecture of a
source, a number of about 20 instrument settings and
potentially the mobile phase, have an impact on ioniza-
tion (possibly with formation of adducts) and disinte-
gration. Therefore, it is questionable whether disinte-
gration spectra libraries like for GC-MS can ever be
established for LC-TMS to allow identification of un-
known compounds. 
The possibility to develop an LC-TMS method criti-
cally depends on the availability of appropriate internal
standard compounds and this is not given in all ana-
lytes of interest at present. For example, specific moni-
toring of the active metabolites of azathioprine, the
mono-, di-, and triphosphates of 6-thioguanine, would
be clinically highly relevant but so far no internal stan-
dards are available for this purpose.
Complementary MS Techniques
It is the intention of this article to summarize concisely
the basic characteristics of LC-MS applications that are
most relevant for clinical laboratories. In fact, beyond
quantification applying multiple reaction monitoring,
LC-TMS offers further analytical possibilities for struc-
tural elucidation of compounds like the so-called sur-
vey scan, the precursor-ion scan, and the neutral loss
scan that are not described here. 
A complementary mass spectrometric technique
that is currently a most important and versatile re-
search tool in “proteomics” but also has potential for
routine application is MALDI-TOF. This represents the
combination of a laser-based ionization technique (ma-
trix-assisted laser desorption ionization, MALDI) from
solid samples like dried serum spots and the very pow-
erful principle of time-of-flight (TOF) mass spectrome-
try of macromolecules. By using specialized transfor-
mation software, sequencing of proteins and amplified
DNA is possible with this technique (in principle, how-
ever, this is also feasible with electrospray LC-TMS). 
In so-called ion-trap instruments – sharing the princi-
ples of atmospheric pressure ionization with LC-TMS –
selected parent and product ions are kept as a cloud
within a radiofrequency field. Disintegration of selected
ions is performed discontinuously by radio frequency
impulses and thus potentially “MSn in time” with sev-
eral generations of product ions is possible instead of
MS/MS (“MS2 “) “in space” as in LC-TMS, enabling
even more specific analyses despite lower instrument
costs compared to TMS systems. However, the discon-
tinuous manner of signal generation in ion-trap instru-
ments limits the number of data points generated
“over” an LC peak, potentially resulting in limited pre-
cision of the assays.
Future Developments
At present, calibration materials, quality control mate-
rials, internal standard compounds, equipment and
supplies for sample preparation, and chromatography
are not yet commercially available as complete kits. It is
likely, however, that the diagnostic industry has recog-
nized LC-TMS as an up-coming routine clinical chem-
istry technique with potentially widespread use and
will provide the market with appropriate products
soon, most importantly with a variety of stable isotope-
labeled internal standard compounds. 
Further technical development of LC-TMS instru-
ments will probably result in increased sensitivity, es-
pecially enabling the quantitative analysis of endoge-
nous compounds circulating in very low concentration
ranges. Furthermore, it seems likely that LC-TMS will
be used as a technological platform for the develop-
ment of automatized complete analyzer solutions com-
bining sample preparation and mass spectrometric
analysis as selective random-access analyzers with
specific application fields complementary to clinical
chemistry and immunoanalyzers. 
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Conclusion
In summary, LC-TMS is an important new technology
substantially extending the analytical spectrum of the
clinical laboratory. LC-TMS is not merely a powerful
new detection principle for HPLC (as applies for single-
stage LC-MS), but represents an analytical principle on
its own with HPLC used for sample preparation. LC-
TMS offers highest analytical versatility and productiv-
ity combined with excellent practicability in a routine
setting and will probably gain far more widespread use
than GC-MS in the future.
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